Loading...
•
Dec 31, 2023
ProKidney Q4 2023 Earnings Report
Prokidney reported full year 2023 financial results and recent corporate highlights.
Key Takeaways
ProKidney Corp. reported its full-year 2023 financial results, highlighting positive interim Phase 2 data for rilparencel and key corporate updates, including the appointment of Dr. Bruce Culleton as CEO and Nikhil Pereira-Kamath as Chief Business Officer. The company's cash, cash equivalents, and marketable securities totaled $363.0 million as of December 31, 2023, expected to fund operations into the fourth quarter of 2025.
Dr. Bruce Culleton was appointed as ProKidney CEO in November.
Nikhil Pereira-Kamath was appointed as Chief Business Officer.
Positive interim Phase 2 RMCL-002 study data was reported in November, demonstrating the potential of rilparencel to preserve kidney function.
Manufacturing has been temporarily paused while ProKidney amends the PROACT 1 protocol.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...